Intelligent Bio Solutions Advances in FDA Approval Process - TipRanks.com
Intelligent Bio Solutions (INBS) announces progress in its clinical study plan, aiming for FDA 510(k) submission for non-invasive drug screening tech by late 2024. The company is conducting a method comparison study with CenExel, comparing fingerprint sweat opiate screening with LC-MS/MS methods, with completion targeted for September. The technology promises quick, hygienic, and accurate drug screening.
Reference News
Intelligent Bio Solutions (INBS) announces progress in its clinical study plan, aiming for FDA 510(k) submission for non-invasive drug screening tech by late 2024. The company is conducting a method comparison study with CenExel, comparing fingerprint sweat opiate screening with LC-MS/MS methods, with completion targeted for September. The technology promises quick, hygienic, and accurate drug screening.